Alzheimer's Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Alzheimer's Disease stocks.

Alzheimer's Disease Stocks Recent News

Date Stock Title
May 15 AVXL Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?
May 15 ACAD Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
May 15 ABOS Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
May 15 ABOS Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
May 14 ABOS Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript
May 14 ALZN Alzamend Neuro Announces Initial Closing of Private Placement
May 14 AVXL Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
May 14 ABOS Acumen Pharmaceuticals GAAP EPS of -$0.25
May 14 ABOS Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
May 13 ABOS Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13 ACIU Sector Update: Health Care Stocks Mixed Late Afternoon
May 13 ACIU Top Midday Gainers
May 13 ACIU Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
May 13 ACIU Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy
May 13 ACIU AC Immune rockets 47% on Alzheimer's therapy deal with Takeda
May 13 AMED Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
May 13 ACIU Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
May 13 ANVS Annovis Bio GAAP EPS of -$0.10 beats by $0.53
May 13 ANVS Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
May 13 ACIU Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags